Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,529 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Isoform-selective TGF-β3 inhibition for systemic sclerosis.
Sun T, Vander Heiden JA, Gao X, Yin J, Uttarwar S, Liang WC, Jia G, Yadav R, Huang Z, Mitra M, Halpern W, Bender HS, Brightbill HD, Wu Y, Lupardus P, Ramalingam T, Arron JR. Sun T, et al. Among authors: yadav r. Med. 2024 Feb 9;5(2):132-147.e7. doi: 10.1016/j.medj.2023.12.011. Epub 2024 Jan 24. Med. 2024. PMID: 38272035 Free article.
Utilizing PK and PD Biomarkers to Guide the First-in-Human Starting Dose Selection of MTBT1466A: A Novel Humanized Monoclonal Anti-TGFβ3 Antibody for the Treatment of Fibrotic Diseases.
Yadav R, Sukumaran S, Lutman J, Mitra MS, Halpern W, Sun T, Setiadi AF, Neighbors M, Sheng XR, Yip V, Shen BQ, Liu C, Han L, Ovacik AM, Wu Y, Glickstein S, Kunder R, Arron JR, Pan L, Kamath AV, Stefanich EG. Yadav R, et al. J Pharm Sci. 2023 Nov;112(11):2910-2920. doi: 10.1016/j.xphs.2023.07.005. Epub 2023 Jul 8. J Pharm Sci. 2023. PMID: 37429356 Free article.
A Phase 1a Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7303509, an Anti-TGFβ3 Antibody, in Healthy Volunteers.
Han LW, Jamalian S, Hsu JC, Sheng XR, Yang X, Yang X, Monemi S, Hassan S, Yadav R, Tuckwell K, Kunder R, Pan L, Glickstein S. Han LW, et al. Among authors: yadav r. Rheumatol Ther. 2024 Jun;11(3):755-771. doi: 10.1007/s40744-024-00670-5. Epub 2024 Apr 25. Rheumatol Ther. 2024. PMID: 38662148 Free PMC article.
High-Throughput Analyses of Therapeutic Antibodies Using High-Field Asymmetric Waveform Ion Mobility Spectrometry Combined with SampleStream and Intact Protein Mass Spectrometry.
Shi RL, Dillon MA, Compton PD, Sawyer WS, Thorup JR, Kwong M, Chan P, Chiu CPC, Li R, Yadav R, Lee GY, Gober JG, Li Z, ElSohly AM, Ovacik AM, Koerber JT, Spiess C, Josephs JL, Tran JC. Shi RL, et al. Among authors: yadav r. Anal Chem. 2023 Nov 28;95(47):17263-17272. doi: 10.1021/acs.analchem.3c03158. Epub 2023 Nov 13. Anal Chem. 2023. PMID: 37956201
Translational PK/PD and the first-in-human dose selection of a PD1/IL15: an engineered recombinant targeted cytokine for cancer immunotherapy.
Yadav R, Schubbert S, Holder PG, Chiang EY, Kiabi N, Bogaert L, Leung I, Rashid R, Avery KN, Bonzon C, Desjarlais JR, Sanjabi S, Sharma A, Lepherd M, Shelton A, Chan P, Liu Y, Joslyn L, Hosseini I, Stefanich EG, Kamath AV, Bernett MJ, Shivva V. Yadav R, et al. Front Pharmacol. 2024 Jun 3;15:1380000. doi: 10.3389/fphar.2024.1380000. eCollection 2024. Front Pharmacol. 2024. PMID: 38887559 Free PMC article.
Comparative Pharmacokinetics and Safety Assessment of 1st- and 2nd-Generation Zinpentraxin Alfa Drug Products in Healthy Volunteers: A Randomized Crossover Study.
Mai TH, Yadav R, Arjomandi A, Jung C, Meier MM, Donaldson F, Zhao R, Ding HT, Hsu JC, Kamath N, Pan L. Mai TH, et al. Among authors: yadav r. Clin Pharmacol Drug Dev. 2024 Jun;13(6):655-664. doi: 10.1002/cpdd.1403. Epub 2024 Apr 23. Clin Pharmacol Drug Dev. 2024. PMID: 38651245 Clinical Trial.
3,529 results